Shares of Aurobindo Pharma hit a fresh 52-week low of Rs 728.50 as they fell 3.4 per cent on the BSE in intra-day trade on Tuesday. The pharmaceutical company’s stock has declined 12 per cent in the past three trading days after the company reported a disappointing operational performance in the June 2021 quarter (Q1FY22), amid a decline across the US market and antiretroviral (ARVs). The stock of the pharmaceutical company was trading at its lowest level since June 2020. In the past month, it has lost 25 per cent compared to a 4.4 per cent rise in the S&P BSE Sensex.

• NTPC Green Energy Adds 50 MW Solar Power in Rajasthan
• Coffee Day Enterprises Settles Rs 25 Cr Loan With Kemfin
• GST Collections Rise 14.7% to Rs 2.04 Lakh Crore in September
• GPT Infraprojects Bags Rs 385 Cr South Africa Rail Order
• Cabinet Backs Rs 1.86 Lakh Cr Plan for Green Power Grid

In Q1FY22, the company’s profit after tax (PAT) was down 1.7 per cent year-on-year (YoY) and 4 per cent quarter-on-quarter (QoQ) at Rs 770 crore. It was, however, in line with analysts’ estimate on higher than expected other income and a lower tax rate. Revenue, meanwhile, de-grew 3.8 per cent YoY and 5 per cent QoQ to Rs 5,702 crore.